All News
Filter News
Found 4,569 articles
-
Genotyping Assay Market Size - Quantitative Research By QYResearch Medical
11/30/2022
The global genotyping assay market size was USD 17.7 Billion in 2020 and is expected to register a robust CAGR of 22.4% during the forecast period.
-
BMS is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.
-
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
11/29/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epilepsies.
-
BioMarin Pharmaceutical announced the FDA no longer plans to hold an advisory committee meeting to review its BLA for Roctavian an AAV gene therapy for adults with severe hemophilia A.
-
FDA Approves CSL-uniQure's Hemophilia B Gene Therapy, the Most Expensive Medicine in the World
11/23/2022
The FDA approved CSL Behring and uniQure’s Hemgenix, a one-time gene therapy developed for adults with Hemophilia B,the companies announced Tuesday afternoon. -
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
11/23/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced advancements in the U.S. Food and Drug Administration (FDA) review of the Biologics License Application (BLA) of ROCTAVIAN™ (valoctocogene roxaparvovec AAV gene therapy) for adults with severe hemophilia A.
-
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
11/22/2022
uniQure N.V. (NASDAQ: QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received approval from the U.S. Food and Drug Administration (FDA) for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.
-
FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
11/22/2022
Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
-
U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
11/22/2022
Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B.
-
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.
-
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
11/17/2022
Sernova Corp. announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 type 1 diabetes (T1D) clinical trial have been implanted with its 10-channel Cell Pouch, which provides >50% more capacity relative to the Cell Pouches used for the first cohort.
-
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
11/17/2022
uniQure N.V. today announced that it will host a Virtual Research & Development Event on Tuesday, November 29, 2022 from 8:30 a.m. to 10:30 a.m. EST.
-
Coagulant Therapeutics Announces Upcoming Oral and Poster Presentations at the 2022 American Society of Hematology (ASH) Annual Meeting
11/16/2022
Coagulant Therapeutics Corporation today announced the acceptance of two abstracts for presentation at the 64th American Society of Hematology (ASH) Annual Meeting.
-
Viral Vector and Plasmid DNA Manufacturing Market Size - Quantitative Research By QYResearch Medical
11/16/2022
The Viral Vector and Plasmid DNA manufacturing market is estimated to reach USD 4.70 billion by 2030 from USD 686.69 million in 2020, delivering a CAGR of 23.8% through the forecast period.
-
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
11/15/2022
Freeline Therapeutics Holdings plc reported financial results for the third quarter of 2022 and announced its decisions to sell its CMC-focused subsidiary in Germany to Ascend Gene and Cell Therapies Ltd., streamline its organization to increase efficiency and strengthen its financial position, and prioritize the development of FLT201 in Gaucher disease and FLT190 in Fabry disease.
-
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis
11/15/2022
CANbridge Pharmaceuticals, Inc. (1228.HK) announced that CAN106, a clinical-stage recombinant humanized monoclonal antibody targeting C5, has been granted Orphan Drug Designation by the United States Food and Drug administration (FDA) for the treatment of myasthenia gravis (MG), an autoimmune neuromuscular disease that causes weakness in skeletal muscles.
-
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
11/15/2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.
-
Ionis Pharmaceuticals inked a collaboration deal with Metagenomi with the goal of adding DNA editing to its RNA-targeted technologies focused on up to four genetic targets.
-
While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.
-
Sobi to present new data at the ASH 2022 Annual Meeting
11/11/2022
Sobi® will present new data at the 64th Annual Meeting of the American Society of Hematology taking place from 10 to 13 December 2022.